deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 7-arm NCT04486352

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP)

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Sponsor: Alliance Foundation Trials, LLC.

Conditions Endometrial Cancer
Interventions Abemaciclib Atezolizumab - 21 Day Cycle Atezolizumab - 28 Day Cycle Bevacizumab Giredestrant Inavolisib Ipatasertib Letrozole Talazoparib Tiragolumab Trastuzumab emtansine
Updated 22 times since 2020 Last updated: Aug 27, 2025 Started: Oct 20, 2021 Primary completion: Oct 1, 2026 Completion: Oct 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04486352, this PHASE1/PHASE2 trial focuses on Endometrial Cancer and remains actively recruiting participants. Sponsored by Alliance Foundation Trials, LLC., it has been updated 22 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Nov 2023 · 8 months · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

22 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 17 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Nov 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Mar 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  8. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  10. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  11. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  13. May 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  14. Mar 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  15. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  16. Oct 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  17. Aug 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alliance Foundation Trials, LLC.
  • Eli Lilly and Company
  • Foundation Medicine
  • Genentech, Inc.
  • Pfizer
Data source: Alliance Foundation Trials, LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Buffalo, United States , Chicago, United States , Duarte, United States , Durham, United States , Englewood, United States , Memphis, United States , Miami Beach, United States , Minneapolis, United States , Morristown, United States and 11 more locations